Safety of the therapy with topical calcineurin inhibitors;Bezpieczeństwo leczenia miejscowymi inhibitorami kalcyneuryny

Dermatologia Kliniczna

Volumn 7, Issue 3, 2005, Pages 129-133

  Szepietowski, Jacek ^a   Reich, Adam ^a   Baran, Eugeniusz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Adverse effects; Atopic dermatitis; Pimecrolimus; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; CARCINOGENESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; REVIEW;

EID: 24644439323     PISSN: 17307201     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Białynicki-Birula R., Baran W., Szepietowski J.: Pimekrolimus krem - nowy niesteroidowy lek przeciwzapalny. Dermatol. Klin., 2004, 6, 103-107.
2. Gliński W., Kruszewski J., Silny W., Kurzawa R., Czarnecka-Operacz M., Baran E., Szepietowski J.: Postȩpowanie diagnostyczno- profilaktyczno-lecznicze w atopowym zapaleniu skóry. Konsensus grupy roboczej specjalistów krajowych ds. dermatologii i wenerologii oraz alergologii. Pol. Merk. Lek., 2004, 17, Supl. 3, 3-15.
3. Crutchfield C.E.: Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis, 2002, 70, 207-208.
4. Kempers S., Boguniewicz M., Carter E., Jarratt M., Pariser D., Stewart D., Stiller M., Tschen E., Chon K., Wissen S., Abrams B.: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol., 2004, 51, 515-525.
5. Allen B.R., Lakhanpaul M., Morris A., Lateo S., Davies T., Scott G., Cardno M., Ebelin M.-E., Burtin P., Stephenson T.J.: Systemic exposure, tolerability, and efficacy of pimekrolimus cream 1% in atopic dermatitis patients. Arch. Dis. Child., 2003, 88, 969-973.
6. FDA alert for healthcare professionals. Pimecrolimus (marketed as Elidel) www.fda.gov/cder/drug/InfoSheets/HCP/ElidelHCP.pdf
7. FDA alert for healthcare professionals. Tacrolimus (marketed as Protopic) www.fda.gov/cder/drug/lnfoSheets/HCP/ProtopicHCP.pdf
8. Szepietowski J., Reich A., Białynicki-Birula R.: Świa̧d w atopowym zapaleniu skóry: obraz kliniczny, patogeneza oraz rola pimekrolimusu w redukcji świa̧du. Dermatol. Klin., 2004, 6, 173-176.
9. Ständer S., Luger T.A.: Antipruritische Wirkung von Pimecrolimus und Tacrolimus. Hautarzt, 2003, 54, 413-417.
10. Pascual J.C., Fleisher A.B.: Tacrolimus ointment (Protopic) for atopic dermatitis. Skin Therapy Lett., 2004, 9, 1-5.
11. Ashcroft D.M., Dimmock P., Garside R., Stein K., Williams H.C.: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. Br. Med. J., 2005, 330, 516.
12. Kaufmann R., Fölster-Holst R., Höger P., Thaçi D., Löffler H., Staab D., Bräutigam M., for the CASM981CDE04-Study Group: Onset of action of pimekrolimus cream 1% in the treatment of atopic eczema in infants. J. Allergy Clin. Immunol., 2004, 114, 1183-1188.
13. Ho V.C., Gupta A., Kaufmann R., Todd G., Vanaclocha F., Takaoka R., Fölster-Holst R., Potter P., Marschal K., Thurston M., Bush C., Cherill R.: Safety and efficacy of nonsteroid pimekrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr., 2003, 142, 155-162.
14. Luger T., Van Leent E.J.M., Graeber M., Hedgecock S., Thurston M., Kandra A., Berth-Jones J., Bjerke J., Christophers E., Knop J., Knulst A.C., Morren M., Morris A., Reitamo S., Roed-Petersen J., Schoepf E., Thestrup-Pedersen K., Van Der Valk P.G., Bos J.D.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol., 2001, 144, 788-794.
15. Luger T.A., Lahfa M., Folster-Holst R., Gulliver W.P., Allen R., Molloy S., Barbier N., Paul C., Bos J.D.: Long-term safety and tolerability of pimecrolimus cream 1%and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Dermatol. Treat., 2004, 15, 169-178.
16. Boguniewicz M., Fiedler V.C., Raimer S., Lawrence I.D., Leung D.Y.M., Hanifin J.M.: A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J. Allergy Clin. Immunol., 1998, 102, 637-644.
17. Reitamo S., Rustin M., Ruzicka T., Cambazard F., Kalimo K., Friedmann P.S., Schoepf E., Lahfa M., Diepgen T.L., Judodihardjo H., Wollenberg A., Berth-Jones J., Bieber T., European Tacrolimus Ointment Study Group: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J. Allergy Clin. Immunol., 2002, 109, 547-555.
18. Reitamo S., Van Leent E.J., Ho V., Harper J., Ruzicka T., Kalimo K., Cambazard F., Rustin M., Taieb A., Gratton D., Sauder D., Sharpe G., Smith C., Junger M., De Prost Y., European/Canadian Tacrolimus Ointment Study Group: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J. Allergy Clin. Immunol., 2002, 109, 539-546.
19. Cheer S.M., Plosker G.L.: Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am. J. Clin. Dermatol., 2001, 2, 389-406.
20. Queille-Roussel C., Paul C., Duteil L., Lefebvre M.C., Rapatz G., Zagula M., Ortonne J.P.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol., 2001, 144, 507-513.
21. Kyllonen H., Remitz A., Mandelin J.M., Elg P., Reitamo S.: Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br. J. Dermatol., 2004, 150, 1174-1181.
22. Siddaiah N., Erickson Q., Miller G., Elston D.M.: Tacrolimus-induced tinea incognito. Cutis, 2004, 73, 237-238.
23. Crawford K.M., Bostrom P., Russ B., Boyd J.: Pimecrolimus-induced tinea incognito. Skinmed, 2004, 3, 352-353.
24. Paul C., Rossi A., Cork M., De Prost Y.: Efficacy and safety of pimekrolimus cream 1% in infants: a combined analysis of a clinical program in 923 patients. J. Am. Acad. Dermatol., 2005, 52, Suppl., P713.
25. Ferrandiz C., Fonseca E., Hernánz J.M., Puig L., Vanaclocha F., Díaz J.M., Macías M.D., Molina X.: Atopic dermatitis in infants: a new highly effective therapy with pimecrolimus (SDZASM 981) cream 1%. J. Eur. Acad. Dermatol. Venerol., 2004, 18, Supl. 2, 375.
26. Patel R.R., Vander Straten M.R., Korman N.J.: The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch. Dermatol., 2003, 139, 1184-1186.
27. Papp K.A., Breuer K., Meurer M., Ortonne J.-P., Potter P.C., De Prost Y., Davidson M.J., Barbier N., Goertz H.-P., Paul C.: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J. Am. Acad. Dermatol., 2005, 52, 247-253.
28. Enke B.U., Bokenkamp A., Offner G., Bartmann P., Brodehl J.: Response to diphtheria and tetanus vaccination in pediatric transplant recipients. Transplantation, 1997, 64, 237-241.
29. Mazzone P.J., Mossad S.B., Mawhorter S.D., Mehta A.C., Schilz R.J., Maurer J.R.: The humoral immune response to influenza vaccination in lung transplant patients. Eur. Respir. J., 2001, 18, 971-976.